Biosimilar Insulin Glargine For Diabetes Management -An Explanation

Speciality: Endocrinology


Speaker:

Dr. Anoop Mishra | Executive Chairman Fortis

Dr. Jothydev | Chairman and Managing Director

Dr. J J Mukherjee | Sr. Consultant Endocrinology at Apollo Gleneagles Hospital

Dr. Vijay Megalur | Medical Director & CEO at Dr Negulaurs Diabetes & Thyroid Specialities Center

Dr. Gayani Samarasinghe | Consultant Endocrinologist District General Hospital - Nawalapitiya

Dr. Viraj Suvarna | VP and Head, Medical Affairs, Biocon Biologics

Description:

A warm welcome to all the medical practitioners in this interesting session of biosimilar insulin Glargine.

Insulin is a hormone secreted from pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that helps in controlling diabetes in patients.

The speakers Dr. Anoop Mishra and panel has provided an elaborative knowledge on biosimilar insulin Glargine in the management of diabetes in patients. 

Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. Insulin glargine is a synthetic version of human insulin that is FDA approved to treat adults and children. It is long-acting with the ability to control sugar all day long.

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

2.

Relationship-building key to addressing oncologist shortages in rural care

3.

A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.

4.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

5.

Prostate cancer therapies: AI-based image analysis detects early organ damage


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot